Ciclesonida

Resumen

Alternativas con registro en Colombia

• Beclometasona · costo anual estimado $ 8.918.775
• Budesonida · costo anual estimado $ 3.134.620
• Fluticasona · costo anual estimado $ 159.098.025

Estudios clínicos principales

• A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years
  Fase 3 · 2009 · 1.110 participantes · Sumitomo Pharma America, Inc. · NCT00953147 · PubMed 22370530
• Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis
  Fase 3 · 2008 · 707 participantes · Sumitomo Pharma America, Inc. · NCT00790023 · PubMed 21130386
• Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to M
  Fase 3 · 2009 · 671 participantes · Sumitomo Pharma America, Inc. · NCT01010971 · PubMed 22370531
• Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.
  Fase 3 · 2006 · 528 participantes · AstraZeneca · NCT00392288

Enfermedades relacionadas

• Asma
• EPOC (enfermedad pulmonar obstructiva crónica)

Fuentes

• Etiqueta FDA (DailyMed): Omnaris